Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures

P. Hande Özdinler; Richard B. Silverman

doi:10.1021/ml500404b

Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures

P. Hande Özdinler^*, Richard B. Silverman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases, involving both cortical and spinal components of motor neuron circuitry and non-neuronal cells that support the motor neurons. There is no effective therapeutic for ALS, and compounds that have extended the lifespan of ALS mouse models have failed in clinical trials. This viewpoint discusses current information regarding the changing views about ALS and what the failures in clinical trials can teach us in the search for an effective treatment. Previous challenges and roadblocks in drug discovery for ALS are noted, and solutions to current limitations are discussed. Learning from the past and moving forward with a new mindset can translate into successful and effective treatment strategies in ALS and other related diseases.

Original language	English (US)
Pages (from-to)	1179-1181
Number of pages	3
Journal	ACS Medicinal Chemistry Letters
Volume	5
Issue number	11
DOIs	https://doi.org/10.1021/ml500404b
State	Published - Nov 13 2014

ASJC Scopus subject areas

Drug Discovery
Biochemistry
Organic Chemistry

Access to Document

10.1021/ml500404b

Cite this

@article{ff8385a4fe0a41b7a1a5b29112de2a3a,

title = "Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures",

abstract = "Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases, involving both cortical and spinal components of motor neuron circuitry and non-neuronal cells that support the motor neurons. There is no effective therapeutic for ALS, and compounds that have extended the lifespan of ALS mouse models have failed in clinical trials. This viewpoint discusses current information regarding the changing views about ALS and what the failures in clinical trials can teach us in the search for an effective treatment. Previous challenges and roadblocks in drug discovery for ALS are noted, and solutions to current limitations are discussed. Learning from the past and moving forward with a new mindset can translate into successful and effective treatment strategies in ALS and other related diseases.",

author = "{\"O}zdinler, {P. Hande} and Silverman, {Richard B.}",

note = "Publisher Copyright: {\textcopyright} 2014 American Chemical Society.",

year = "2014",

month = nov,

day = "13",

doi = "10.1021/ml500404b",

language = "English (US)",

volume = "5",

pages = "1179--1181",

journal = "ACS Medicinal Chemistry Letters",

issn = "1948-5875",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - Treatment of amyotrophic lateral sclerosis

T2 - Lessons learned from many failures

AU - Özdinler, P. Hande

AU - Silverman, Richard B.

PY - 2014/11/13

Y1 - 2014/11/13

N2 - Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases, involving both cortical and spinal components of motor neuron circuitry and non-neuronal cells that support the motor neurons. There is no effective therapeutic for ALS, and compounds that have extended the lifespan of ALS mouse models have failed in clinical trials. This viewpoint discusses current information regarding the changing views about ALS and what the failures in clinical trials can teach us in the search for an effective treatment. Previous challenges and roadblocks in drug discovery for ALS are noted, and solutions to current limitations are discussed. Learning from the past and moving forward with a new mindset can translate into successful and effective treatment strategies in ALS and other related diseases.

AB - Amyotrophic lateral sclerosis (ALS) is one of the most complex neurodegenerative diseases, involving both cortical and spinal components of motor neuron circuitry and non-neuronal cells that support the motor neurons. There is no effective therapeutic for ALS, and compounds that have extended the lifespan of ALS mouse models have failed in clinical trials. This viewpoint discusses current information regarding the changing views about ALS and what the failures in clinical trials can teach us in the search for an effective treatment. Previous challenges and roadblocks in drug discovery for ALS are noted, and solutions to current limitations are discussed. Learning from the past and moving forward with a new mindset can translate into successful and effective treatment strategies in ALS and other related diseases.

UR - http://www.scopus.com/inward/record.url?scp=84927611059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927611059&partnerID=8YFLogxK

U2 - 10.1021/ml500404b

DO - 10.1021/ml500404b

M3 - Article

C2 - 25408825

AN - SCOPUS:84927611059

SN - 1948-5875

VL - 5

SP - 1179

EP - 1181

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

IS - 11

ER -

Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this